about
Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesisEpigenetic therapy in gastrointestinal cancer: the right combinationG-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer.Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinomaGenome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma.A high-fat diet regulates gastrin and acid secretion through primary cilia.Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancerPeptide receptor targeting in cancer: the somatostatin paradigm.GABAergic control of depression-related brain statesEpigenetics of gestational diabetes mellitus and offspring health: the time for action is in early stages of life.Methylation of serum SST gene is an independent prognostic marker in colorectal cancer.Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer.Neuroendocrine factors: The missing link in non‑melanoma skin cancer (Review).HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis.Epigenetic control of cancer by neuropeptides.Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers.The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis.
P2860
Q21134097-682DE464-C02F-42C1-978D-05453BF7C46BQ26745709-3D98C749-0C2D-4C4A-8C9B-8A02FBD82177Q26801162-FE953D88-22FB-433B-99E3-5DDC012B4E32Q35130509-AD98A1F5-FAD8-4E82-948A-7E94ED62597FQ35143989-5F952707-04C2-4628-A0A7-4925582A4685Q35911266-2BA74C06-9EA4-4959-91F5-DB82284271B9Q36117413-53076327-7B74-41B7-8274-0ADB406187C0Q36317734-2E71064E-A262-4A4F-99E8-07567E561B47Q36638046-549BBDFC-F381-446C-AB0C-6BD2102A1B9BQ36668325-27F43066-6792-4D4E-98E0-4818406DE62CQ36950149-710C3A14-2B2E-40A5-9F01-9C602625FCAEQ37298333-BF542F47-E060-4C96-845D-EAFA95FDCDE6Q37326746-5C827305-96CD-4C90-88CC-8B4C71B7AA21Q38676352-A3C8ED9B-4E3F-41F9-9105-271B7203DE08Q38913348-22B47DF2-63DF-4AC9-B578-52B60BF1C473Q38998556-DFAF162D-1EE9-41E4-B680-9E556B5E768DQ50252299-0CA08D76-73E5-4D29-B4F8-366C88DAA8AFQ55346706-6532927E-B219-4F72-BABB-8BBD2B1A2A76
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Epigenetic silencing of somatostatin in gastric cancer.
@ast
Epigenetic silencing of somatostatin in gastric cancer.
@en
Epigenetic silencing of somatostatin in gastric cancer.
@nl
type
label
Epigenetic silencing of somatostatin in gastric cancer.
@ast
Epigenetic silencing of somatostatin in gastric cancer.
@en
Epigenetic silencing of somatostatin in gastric cancer.
@nl
prefLabel
Epigenetic silencing of somatostatin in gastric cancer.
@ast
Epigenetic silencing of somatostatin in gastric cancer.
@en
Epigenetic silencing of somatostatin in gastric cancer.
@nl
P2093
P2860
P1476
Epigenetic silencing of somatostatin in gastric cancer.
@en
P2093
Dana Marshal
DunFa Peng
Kaya Jackson
Mohammed Soutto
TianLing Hu
Wael El-Rifai
P2860
P2888
P304
P356
10.1007/S10620-010-1422-Z
P577
2010-10-07T00:00:00Z
P5875
P6179
1015142666